inclusion criteria: * provision of informed consent by the participant or authorized representative * age ≥18 years * confirmed sars-cov-2 by nucleic acid testing in the past 5 days * covid-19 related symptom initiation within 5 days * female patients of childbearing potential must have a negative pregnancy test at screening. female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment.

inclusion criteria: * provision of informed consent by the participant or authorized representative * age ≥18 years * confirmed sars-cov-2 by nucleic acid testing in the past 5 days * covid-19 related symptom initiation within 5 days * female patients of childbearing potential must have a negative pregnancy test at screening. female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment.

inclusion criteria: - provision of informed consent by the participant or authorized representative - age ≥18 years - confirmed sars-cov-2 by nucleic acid testing in the past 5 days - covid-19 related symptom initiation within 5 days - female patients of childbearing potential must have a negative pregnancy test at screening. female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment.

inclusion criteria: - provision of informed consent by the participant or authorized representative - age ≥18 years - confirmed sars-cov-2 by nucleic acid testing in the past 5 days - covid-19 related symptom initiation within 5 days - female patients of childbearing potential must have a negative pregnancy test at screening. female patients of childbearing potential and fertile male patients who are sexually active with a female of childbearing potential must use highly effective methods of contraception throughout the study and for 1 week following the last dose of study treatment.